Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Lucas

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Biorxiv : the Preprint Server for Biology|September 25, 2023
WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line modelAshuvinee Elangovan, Emily A Bossart, Ahmed Basudan, et al.
The Journal of Clinical Investigation|January 22, 2020
GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoproteinJing Cheng, Linda R Klei, Nathaniel E Hubel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2024
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
Cancer Research|December 21, 2017
The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast CancerPrasanna Ekambaram, Jia-Ying Lloyd Lee, Nathaniel E Hubel, et al.
Molecular Cancer Research : MCR|October 26, 2018
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast CancerAhmed Basudan, Nolan Priedigkeit, Ryan J Hartmaier, et al.
Human Pathology|June 18, 2026
A Report of Thirteen Non-Conventional FLCN-Mutated (Renal) Tumors (FMT) and a Discussion of Proposed Diagnostic Criteria, Convergent FLCN/TFEB and FLCN/MITF E318K Signaling, and FLCN immunohistochemistrySounak Gupta, Rosalie M Sterner, Hisashi Hasumi, et al.
Endocrinology|May 8, 2021
A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer MetastasisRebecca J Watters, Kostas Verdelis, Peter C Lucas, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Biorxiv : the Preprint Server for Biology|September 25, 2023
WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line modelAshuvinee Elangovan, Emily A Bossart, Ahmed Basudan, et al.
The Journal of Clinical Investigation|January 22, 2020
GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoproteinJing Cheng, Linda R Klei, Nathaniel E Hubel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2024
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
Cancer Research|December 21, 2017
The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast CancerPrasanna Ekambaram, Jia-Ying Lloyd Lee, Nathaniel E Hubel, et al.
Molecular Cancer Research : MCR|October 26, 2018
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast CancerAhmed Basudan, Nolan Priedigkeit, Ryan J Hartmaier, et al.
Human Pathology|June 18, 2026
A Report of Thirteen Non-Conventional FLCN-Mutated (Renal) Tumors (FMT) and a Discussion of Proposed Diagnostic Criteria, Convergent FLCN/TFEB and FLCN/MITF E318K Signaling, and FLCN immunohistochemistrySounak Gupta, Rosalie M Sterner, Hisashi Hasumi, et al.
Endocrinology|May 8, 2021
A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer MetastasisRebecca J Watters, Kostas Verdelis, Peter C Lucas, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Pageof 12